Plus Therapeutics (NASDAQ:PSTV) Trading Up 2.8% – What’s Next?

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) were up 2.8% on Friday . The company traded as high as $1.45 and last traded at $1.45. Approximately 18,763 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 58,205 shares. The stock had previously closed at $1.41.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PSTV shares. Ascendiant Capital Markets decreased their target price on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Plus Therapeutics in a report on Friday, August 16th.

Plus Therapeutics Stock Up 2.1 %

The firm has a 50 day moving average of $1.44 and a 200-day moving average of $1.73. The company has a market cap of $8.21 million, a P/E ratio of -0.47 and a beta of 0.67.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.71) EPS for the quarter. The firm had revenue of $1.28 million during the quarter. On average, research analysts predict that Plus Therapeutics, Inc. will post -2 EPS for the current fiscal year.

Institutional Investors Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.